The hidden dangers in chemical hair relaxers your patients need to know

Written by The Life Science Feed Editorial Team · Published 10 August 2026 · Edited by Mara Voss

For many patients, chemical hair relaxers are a routine part of their beauty regimen, a tool for achieving desired hair textures. But beneath the surface of straightened hair lies a growing body of evidence linking these products to serious health concerns, including uterine fibroids, endometriosis, and certain hormone-sensitive cancers. Clinicians must understand these risks to provide informed guidance.

KEY TAKEAWAYS

- The Pivot: Emerging data connects chemical hair relaxer use to increased risks of several gynecological and endocrine-related conditions.
- The Data: Consistent use of these products, particularly among women of color, correlates with higher incidence of uterine fibroids and certain cancers.
- The Action: GPs and specialists should proactively discuss the potential health implications of chemical hair relaxers with patients, especially those with a family history of relevant conditions.

Chemical hair relaxers, often marketed as 'perms' or 'straighteners,' contain a complex mixture of chemicals designed to permanently alter the hair's protein structure. These products typically use strong alkaline agents, such as sodium hydroxide (lye), calcium hydroxide, or guanidine carbonate, to break the disulfide bonds in the hair cortex. The process involves applying the chemical mixture to the hair, allowing it to penetrate and disrupt the bonds, followed by rinsing and neutralizing. This chemical alteration results in a straightened hair texture that can last for several weeks until new hair growth requires reapplication. The widespread use of these products, particularly within specific demographic groups, has made them a significant public health consideration.

The chemical composition of hair relaxers is diverse, but common ingredients include phthalates, parabens, formaldehyde-releasing chemicals, and various phenols. Phthalates, such as diethyl phthalate (DEP) and dibutyl phthalate (DBP), are often used as plasticizers and solvents, but they are also known endocrine-disrupting chemicals (EDCs). Parabens, like methylparaben and propylparaben, function as preservatives and also exhibit estrogenic activity. Formaldehyde releasers, such as DMDM hydantoin, are used for preservation but can release formaldehyde, a known carcinogen, upon degradation. These chemicals are not merely topical; they can be absorbed through the scalp, especially when the scalp is irritated or compromised, entering the systemic circulation and potentially exerting effects on various organ systems.

The mechanism of systemic exposure

The scalp is a highly vascularized area, and any disruption to its integrity can facilitate the absorption of chemicals into the bloodstream. Chemical hair relaxers are inherently irritating; their mechanism of action involves breaking down protein structures, which can lead to scalp burns, lesions, and inflammation. These micro-abrasions and inflammatory responses create direct pathways for chemical absorption. The prolonged contact time of these products with the scalp, often for 20 to 60 minutes during application, increases the opportunity for systemic uptake. The heat generated during the relaxing process, or the use of heat styling tools afterward, can also enhance chemical penetration.

Once absorbed, EDCs can mimic or interfere with the body's natural hormones, particularly estrogens. This endocrine disruption is a key concern, as estrogen plays a critical role in the development and progression of several gynecological conditions and hormone-sensitive cancers. For instance, phthalates and parabens have been shown in preclinical studies to bind to estrogen receptors, altering cellular signaling pathways. This can lead to an overexpression of estrogenic effects or, conversely, block natural hormone action, both of which can have detrimental consequences for reproductive health and cancer risk. The cumulative exposure from regular use over many years amplifies these potential effects.

The link to uterine fibroids and endometriosis

Uterine fibroids, or leiomyomas, are benign tumors of the uterus that affect a substantial proportion of women, particularly women of color. Symptoms can range from heavy menstrual bleeding and pelvic pain to infertility. The etiology of fibroids is complex, but estrogen and progesterone play important roles in their growth. Exposure to EDCs from hair relaxers is hypothesized to contribute to fibroid development by altering hormonal balance and promoting cellular proliferation in the uterus. Studies have consistently shown a correlation between frequent and long-term use of chemical hair relaxers and an increased risk of uterine fibroids. The risk appears to be dose-dependent, with more frequent use and longer duration of use associated with higher incidence.

Endometriosis, another estrogen-dependent condition, involves the growth of endometrial-like tissue outside the uterus, causing chronic pelvic pain, dysmenorrhea, and infertility. The inflammatory and hormonal dysregulation induced by EDCs is a plausible mechanism for its development and progression. While direct causal links are still under investigation, the biological plausibility of EDCs contributing to endometriosis is strong. The systemic absorption of chemicals that interfere with estrogen signaling could promote the survival and proliferation of ectopic endometrial tissue, exacerbating the condition. Patients presenting with unexplained chronic pelvic pain or infertility should be questioned about their use of these products as part of a comprehensive history.

Cancer risks and other endocrine disruptions

The most concerning associations involve an increased risk of certain cancers, particularly hormone-sensitive ones. Breast cancer, ovarian cancer, and uterine cancer have all been implicated. The estrogenic activity of many hair relaxer chemicals can promote the growth of hormone-receptor-positive breast cancer cells. Long-term exposure to these EDCs may increase the risk of developing such cancers, especially in genetically predisposed individuals or those with other risk factors. The latency period for cancer development means that effects from exposures in adolescence or early adulthood may not manifest until decades later, complicating direct attribution but not diminishing the concern.

Ovarian cancer, particularly certain epithelial subtypes, is also influenced by hormonal factors. The chronic inflammation and endocrine disruption caused by absorbed chemicals could contribute to ovarian carcinogenesis. Similarly, uterine cancer, specifically endometrial cancer, is strongly linked to estrogen exposure. Any exogenous source of estrogenic

compounds, including those found in hair relaxers, could theoretically increase this risk. The cumulative burden of these exposures over a patient's lifetime is a critical factor. Clinicians should consider these exposures when evaluating patients with a family history of these cancers or those presenting with symptoms suggestive of early disease.

Beyond cancer, other endocrine disruptions are also a concern. Polycystic ovary syndrome (PCOS), a common endocrine disorder characterized by hormonal imbalance, ovulatory dysfunction, and metabolic issues, could theoretically be influenced by EDCs. While direct evidence linking hair relaxers to PCOS is less robust than for fibroids or cancer, the underlying mechanisms of endocrine disruption suggest a potential connection. Thyroid dysfunction is another area of interest, as some EDCs can interfere with thyroid hormone synthesis and action. These broader endocrine effects highlight the systemic nature of the risks associated with chemical hair relaxer use.

Counseling patients on the risks

Given the accumulating evidence, clinicians have a responsibility to counsel patients about the potential dangers of chemical hair relaxers. This conversation should be approached with sensitivity, recognizing the cultural and personal significance of hair styling practices. The goal is not to dictate choices but to empower patients with accurate information to make informed decisions about their health. A comprehensive patient history should include questions about hair care practices, specifically the type and frequency of chemical relaxer use, and the age at which use began.

When discussing these risks, it is important to explain the concept of endocrine-disrupting chemicals and how they can affect the body's hormonal balance. Patients should understand that these chemicals are absorbed through the scalp, especially when irritation or burns are present. Highlighting the specific links to uterine fibroids, endometriosis, and hormone-sensitive cancers can provide concrete examples of the potential health consequences. For patients already experiencing symptoms such as heavy bleeding, pelvic pain, or difficulty conceiving, this information can be particularly relevant to their diagnostic workup and management plan. The Oxford Handbook of Clinical Medicine provides a concise reference for managing these common presentations.

Patients should be advised on strategies to minimize exposure if they choose to continue using relaxers. This includes ensuring the scalp is healthy and free of cuts or abrasions before application, avoiding frequent touch-ups, and opting for products with fewer known EDCs, though identifying such products can be challenging given current labeling regulations. Encouraging alternative hair styling methods that do not involve harsh chemicals, such as natural hair care routines, can be a valuable part of the discussion. For patients with a strong family history of hormone-sensitive cancers or those with existing fibroids or endometriosis, the recommendation to discontinue relaxer use should be more emphatic.

The conversation should also address the psychological and social aspects of hair. For many, hair relaxers are tied to identity, cultural norms, and professional presentation. Acknowledging these factors and offering resources for exploring natural hair care options can make the discussion more productive and less prescriptive. Providing information on support groups or online communities focused on natural hair transitions can also be beneficial. The long-term health implications often outweigh the immediate aesthetic benefits, but patients need to feel supported in making these difficult choices.

The current regulatory market for cosmetic products in many regions, including Europe, does not always require comprehensive testing for endocrine disruption or long-term carcinogenic effects before market entry. This regulatory gap places a greater burden on clinicians to stay informed and educate their patients. Advocacy for stricter regulations and clearer labeling of chemical ingredients in cosmetic products is an ongoing effort. Until such changes are implemented, patient education remains the primary tool for mitigating these risks. The lack of specific regulatory action on these

products, despite accumulating evidence, is a significant public health concern that warrants continued vigilance from the medical community.

CLINICAL IMPLICATIONS

The accumulating evidence on chemical hair relaxers and their link to uterine fibroids, endometriosis, and certain cancers demands a direct response from clinicians. We can no longer dismiss these products as merely cosmetic; they are a source of systemic chemical exposure with tangible health consequences. GPs and specialists must integrate questions about hair care practices into routine patient histories, particularly for women of color who disproportionately use these products and bear a higher burden of conditions like uterine fibroids.

Ignoring this issue means missing an opportunity for primary prevention and early intervention. When a patient presents with unexplained pelvic pain, heavy menstrual bleeding, or is struggling with infertility, a detailed inquiry into their use of chemical hair relaxers should be as standard as asking about smoking history. The endocrine-disrupting chemicals in these products are not inert; they are absorbed and can actively interfere with hormonal pathways critical to reproductive health and cancer development.

The onus is on us to translate this emerging science into actionable clinical advice. This involves not just informing patients of the risks, but also providing practical alternatives and support for transitioning to less harmful hair care routines. The conversation needs to be culturally sensitive, acknowledging the deep personal and social significance of hair, but it must also be firm about the potential health trade-offs. We owe our patients the full picture, even when it challenges established norms.

This issue highlights a broader regulatory failure in the oversight of cosmetic products. Until robust pre-market testing for endocrine disruption and carcinogenicity becomes standard, clinicians will remain on the front lines, tasked with mitigating risks that should ideally be addressed at the manufacturing and policy levels. Our role is to bridge that gap, ensuring patients are not unknowingly exposed to avoidable health hazards.

EDITORIAL & AI STANDARDS

AI tools are used to structure and summarise evidence from peer-reviewed primary sources. Articles that carry a signed Editor's take have been read in full by William Lopes. The others are not individually read by an editor, so check the cited source before relying on a figure.

REFERENCES

1. 1. Yang Q, Ciebiera M, Bariani MV, et al. Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. Endocr Rev. 2022;43(4):678-719. doi:10.1210/endrev/bnab039
2. 2. Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124(10):1501-1512. doi:10.1111/1471-0528.14640
3. 3. Giuliani E, As-Sanie S, Marsh EE. Epidemiology and management of uterine fibroids. Int J Gynaecol Obstet. 2020;149(1):3-9. doi:10.1002/ijgo.13102
4. 4. Vannuccini S, Petraglia F, Carmona F, Calaf J, Chapron C. The modern management of uterine fibroids-related abnormal uterine bleeding. Fertil Steril. 2024;122(1):20-30. doi:10.1016/j.fertnstert.2024.04.041
5.

5. Keating MK, Jones KB, Hansell MW. Uterine Fibroids: Rapid Evidence Review. Am Fam Physician. 2025;112(4):393-400. PMID:41118184

6. 6. De La Cruz MS, Buchanan EM. Uterine Fibroids: Diagnosis and Treatment. Am Fam Physician. 2017;95(2):100-107. PMID:28084714

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com